Abstract :
Background: Osteoarthritis (OA) is a progressive condition that affects the joints, leading to their gradual degeneration causing stiffness, pain, and mobility issues. Conventional treatments, such as NSAIDs, have significant side effects, leading to interest in nutraceutical alternatives. TriNyros, a combination of Rosehip, IridoForce, and Aflapin, may provide relief with fewer adverse effects. This study aimed to observe the potential NSAID-sparing effect of this combination in patients with OA.
Materials and Methods: The study was a prospective, open-label, real-world evidence program involving 136 OA patients who received TriNyros twice daily for 90 days. Key outcomes included changes in WOMAC scores for stiffness, pain, VAS pain scores, physical function and NSAID usage.
Results: By day 15, 67% of participants reduced NSAID or paracetamol use, and 27.94% maintained symptom control on the combination alone for 90 days. WOMAC scores decreased by 87% (P
Conclusion: The combination of Rosehip, IridoForce, and Aflapin effectively alleviated OA symptoms and reduced reliance on conventional pain medications.
Keyword :
Osteoarthritis, TriNyros, Rosehip, IridoForce, Aflapin, WOMAC score, VAS pain score, Joint pain.